10/17
07:00 am
agio
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
Low
Report
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
10/16
11:05 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/16
08:44 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/10
09:36 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $51.00 price target on the stock.
9/28
07:43 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
9/27
07:41 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $56.00 price target on the stock, down previously from $60.00.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $56.00 price target on the stock, down previously from $60.00.
9/20
11:09 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/19
09:21 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.
9/17
08:07 am
agio
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results [Yahoo! Finance]
9/14
08:44 am
agio
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth [Yahoo! Finance]
Low
Report
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth [Yahoo! Finance]
9/12
06:54 am
agio
Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation [Yahoo! Finance]
9/11
07:00 am
agio
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
Low
Report
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
9/5
07:00 am
agio
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
Medium
Report
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
8/15
08:14 am
agio
Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. [Yahoo! Finance]
Low
Report
Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. [Yahoo! Finance]
8/9
07:37 am
agio
Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now? [Yahoo! Finance]
Low
Report
Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now? [Yahoo! Finance]
8/6
05:50 pm
agio
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
Low
Report
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
8/5
10:48 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
8/4
09:46 am
agio
Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results [Yahoo! Finance]
Medium
Report
Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results [Yahoo! Finance]
8/2
04:00 pm
agio
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $53.00 to $55.00. They now have an "outperform" rating on the stock.
Medium
Report
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target raised by analysts at Royal Bank of Canada from $53.00 to $55.00. They now have an "outperform" rating on the stock.
8/2
08:05 am
agio
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12% [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12% [Yahoo! Finance]
8/1
01:46 pm
agio
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides [Yahoo! Finance]
8/1
06:33 am
agio
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused [Yahoo! Finance]
Medium
Report
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused [Yahoo! Finance]
8/1
06:31 am
agio
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
Medium
Report
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
8/1
06:30 am
agio
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
Medium
Report
Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
7/29
01:06 pm
agio
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Low
Report
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]